Grifols, (GRFS) Receiving Somewhat Positive Media Coverage, Study Finds
Headlines about Grifols, (NASDAQ:GRFS) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Grifols, earned a news impact score of 0.10 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.9709107178145 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the news headlines that may have impacted Accern’s analysis:
- Grifols, SA (GRFS) Stock in the Technical Spotlight – Wall Street Morning (wallstreetmorning.com)
- Grifols, S.A. (GRFS) Receives Average Recommendation of “Hold” from Analysts (americanbankingnews.com)
- Ignyta, Inc., (NASDAQ: RXDX), QIAGEN NV, (NASDAQ: QGEN), Grifols, SA, (NASDAQ: GRFS), Grupo Supervielle SA … – Stocks In The News (press release) (tradingnewsnow.com)
- Grifols : FDA approves a new Grifols test for the genetic diagnosis of alpha-1 antitrypsin deficiency Download (61.1 Kb) (4-traders.com)
Grifols, (NASDAQ:GRFS) traded down $0.13 on Thursday, hitting $23.04. 380,500 shares of the company traded hands, compared to its average volume of 634,402. The company has a debt-to-equity ratio of 1.69, a quick ratio of 1.39 and a current ratio of 3.17. The firm has a market cap of $15,821.01, a PE ratio of 21.45, a P/E/G ratio of 1.69 and a beta of 1.07. Grifols, has a 1 year low of $14.33 and a 1 year high of $24.20.
Several equities analysts recently issued reports on GRFS shares. Citigroup Inc. started coverage on shares of Grifols, in a research note on Tuesday, October 31st. They issued a “buy” rating for the company. Zacks Investment Research cut shares of Grifols, from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Finally, BidaskClub cut shares of Grifols, from a “sell” rating to a “strong sell” rating in a research note on Friday, July 28th. Two analysts have rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $24.00.
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.
Receive News & Ratings for Grifols S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols S.A. and related companies with Analyst Ratings Network's FREE daily email newsletter.